Latest News for QNRX
— Fast Track Designation facilitates development and expedites regulatory review of therapies addressing serious conditions with significant unmet medical need —
Videos on the NETHERTON NOW website have been viewed 2 million times with 24 million impressions ASHBURN, Va., Feb. 26, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – In recognition of Rare Disease Day® 2026, Quoin Pharmaceuticals Ltd.
Confirmation Received from MHLW That QRX003 Qualifies for Both Orphan Drug Designation and Fast Track Regulatory Review Status
QRX003 could become the first ever approved treatment for Netherton Syndrome ASHBURN, Va., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ: QNRX - Get Free Report) saw a large decline in short interest in the month of December. As of December 15th, there was short interest totaling 40,499 shares, a decline of 42.7% from the November 30th total of 70,734 shares. Based on an average trading volume of 130,184 shares, the
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for QNRX.
U.S. House Trading
No House trades found for QNRX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.